Hepatitis C Is Now Curable: Direct-Acting Antiviral Treatments and How to Get Tested

Research-informed explainer — last updated April 12, 2026

Hepatitis C is now curable in more than 95% of patients with an 8-12 week course of direct-acting antiviral pills — yet an estimated 1 million Americans remain undiagnosed and untreated, quietly developing cirrhosis and liver cancer. The shift from months of interferon-based therapy to a short course of well-tolerated oral medications is one of the most dramatic treatment transformations in modern medicine.

This article draws on research from Mark Sulkowski, MD, Professor of Medicine at Johns Hopkins University School of Medicine, who developed the FIB-4 fibrosis index and co-authored the boceprevir New England Journal of Medicine trial; Chloe Thio, MD, at Johns Hopkins Bayview Medical Center, whose IL28B and HLA genetics work explains why some patients clear HCV spontaneously; Peter Ruane, MD, Associate Clinical Professor at UCLA, who co-authored the pivotal sofosbuvir/velpatasvir pan-genotypic trial; Pablo Tebas, MD, Professor of Medicine at the University of Pennsylvania, who led the ledipasvir/sofosbuvir trial in HIV-coinfected patients; and Ronald Nahass, MD, at Hunterdon Medical Center, who contributed to the elbasvir/grazoprevir trial in patients on opioid agonist therapy.

Who Should Be Tested for Hepatitis C

The CDC and USPSTF recommend universal hepatitis C screening for all adults aged 18-79 at least once, and for all pregnant women during each pregnancy. Additional screening is recommended for anyone who has ever injected drugs, received a blood transfusion before 1992, is currently on hemodialysis, is HIV-positive, or has abnormal liver enzymes without clear explanation.

The test is a blood draw for HCV antibody. If positive, a confirmatory HCV RNA test determines whether the infection is active (chronic) or resolved. Approximately 70-80% of people exposed to HCV develop chronic infection; 20-30% clear it spontaneously, a phenomenon influenced by the IL28B genetics characterized by Dr. Thio and collaborators (cited 2,144 times). People who clear spontaneously still test antibody-positive for life, which is why the RNA test is required to distinguish active infection from resolved infection.

Staging Liver Disease Without a Biopsy

Before the era of non-invasive fibrosis markers, staging liver disease required a liver biopsy — a procedure with measurable complication risk. Dr. Sulkowski's Hepatology paper (cited 4,721 times) developed the FIB-4 index using four standard lab values: age, AST, ALT, and platelet count. The resulting score stratifies patients into low, indeterminate, and high probability of significant fibrosis (F2 or greater on the Metavir scale).

FIB-4 below 1.30 has a high negative predictive value for significant fibrosis; FIB-4 above 2.67 has a high positive predictive value for advanced fibrosis. Values between 1.30 and 2.67 are indeterminate and may warrant additional testing with fibroscan (transient elastography) or liver biopsy. This index is now embedded in major HCV management guidelines and eliminates the need for routine biopsy in most treatment-naive patients.

Why Genotype Mattered — and Why It Now Matters Less

Before modern DAAs, HCV genotype was the central determinant of treatment choice, duration, and expected response. Dr. Sulkowski's IL28B Nature paper (cited 3,514 times) identified a common variant near the gene encoding interferon-lambda-3 that predicted treatment response to peginterferon plus ribavirin: patients with the favorable CC genotype had sustained virologic response rates double those of patients with CT or TT genotypes. This pharmacogenomic testing became routine before initiating old-generation regimens.

Modern pan-genotypic DAAs have rendered this distinction largely obsolete for initial treatment decisions. Sofosbuvir/velpatasvir (Epclusa), tested in the trial co-authored by Dr. Ruane (cited 1,110 times), achieved SVR12 rates of 99% in genotypes 1, 2, 4, 5, and 6 — essentially eliminating genotype as a treatment barrier. The trial enrolled 624 previously treated and untreated patients, including some with compensated cirrhosis.

The Main Modern Regimens

Sofosbuvir/velpatasvir (Epclusa) — Once daily for 12 weeks, pan-genotypic, effective in patients with and without cirrhosis. Achieves SVR12 above 95% across all common genotypes. The benchmark regimen for treatment-naive patients without complex resistance profiles.

Glecaprevir/pibrentasvir (Mavyret) — Once daily for 8 weeks in treatment-naive patients without cirrhosis, 12 weeks with compensated cirrhosis. Also pan-genotypic. Provides the shortest treatment course available, with SVR12 above 97%.

Ledipasvir/sofosbuvir (Harvoni) — Once daily for 12 weeks, genotype 1/4/5/6, has extensive clinical data. Dr. Tebas and the ION-4 trial team (cited 465 times) demonstrated that ledipasvir/sofosbuvir for 12 weeks achieved 96% SVR12 in 335 HIV-coinfected patients — confirming that HIV coinfection does not reduce HCV cure rates when drug-drug interactions are managed.

HCV Treatment in People Who Use Drugs

One of the most consequential advances in HCV care has been demonstrating that active drug use or opioid agonist therapy is not a contraindication to treatment. The C-EDGE CO-STAR trial, to which Dr. Nahass contributed (cited 362 times), enrolled 301 patients on methadone or buprenorphine who received elbasvir/grazoprevir for 12 weeks. SVR12 was 91.5% — equivalent to rates in non-drug-using populations in earlier trials.

This evidence has transformed HCV treatment policy in addiction medicine settings. People who inject drugs have the highest incident HCV rates in the United States; treating them — even if reinfection risk persists — reduces onward transmission and prevents progressive liver disease.

What SVR12 Means — and What Happens After Cure

Sustained virologic response at 12 weeks (SVR12), defined as undetectable HCV RNA 12 weeks after completing therapy, is considered virologic cure. The HCV virus is cleared from the blood and liver. In patients without significant fibrosis, liver function and fibrosis markers improve substantially after cure, and liver cancer risk drops toward background.

In patients with cirrhosis or advanced fibrosis at the time of treatment, SVR12 does not eliminate liver cancer risk — ongoing 6-month ultrasound surveillance is recommended even after successful treatment. Curing HCV in a cirrhotic liver prevents further fibrosis but does not reverse existing structural damage.

Dr. Thio's Science paper on HLA and NK receptor genetics (cited 1,180 times) established that immune-mediated viral clearance involves complex interactions between HLA alleles and killer immunoglobulin-like receptors on natural killer cells — findings that helped explain why some patients remained difficult to treat in the interferon era and that continue to inform post-cure immune recovery studies.

Questions to ask your doctor

• Have I been screened for hepatitis C? If my antibody is positive, do I need an RNA test to confirm active infection?
• What is my FIB-4 score, and does it indicate I need additional liver staging before starting treatment?
• Which DAA regimen is most appropriate for my HCV genotype, treatment history, and any co-existing HIV or kidney disease?
• If I have cirrhosis, do I still need liver cancer surveillance after I am cured?
• Are there drug-drug interactions between my current medications and the DAA regimen?
• If I am on methadone or buprenorphine, does that affect treatment eligibility?

The bottom line

Hepatitis C is curable with an 8-12 week course of once-daily oral pills that are well tolerated and effective in over 95% of patients, regardless of genotype or HIV status. The FIB-4 index replaces liver biopsy for most staging decisions, and active drug use is no longer a contraindication to treatment. Anyone born between 1945 and 1965, or who has any of the listed risk factors, should be tested. If the RNA test confirms active infection, a conversation with an infectious disease specialist or hepatologist about immediate treatment is the right next step.